The earnings call highlighted strong performance in the MRD business with significant revenue growth and profitability, improved gross margins, and successful EMR integrations. Despite high operating expenses and a continued loss in the Immune Medicine segment, the company is optimistic about future growth and has raised its full year guidance.

Company Guidance -

Q3 2025

During the call, Adaptive Biotechnologies provided updated guidance, raising their full-year MRD revenue forecast to a range of $190 million to $200 million, reflecting a 31% to 37% growth versus fiscal year 2024. This increase is driven by stronger-than-expected clinical volume performance and higher anticipated MRD milestone revenue, projected to be between $14 million and $15 million. The company also reported a 36% improvement in cash burn for the quarter, reducing it to approximately $11 million, and ended with a solid cash position of $222 million. ClonoSEQ revenue grew 57% year-over-year in the second quarter, with test volumes increasing by 37% to 25,321 tests, and an ASP growth of 17% to $1,290 per test. The MRD business achieved a positive adjusted EBITDA of $1.9 million, marking a significant milestone and setting the stage for continued profitability. The company also highlighted improvements in sequencing gross margin by 14 percentage points year-over-year to 64%, and noted progress in their pharma business with a $218 million backlog, up 21% from the prior year.

MRD Business Profitability

The MRD business achieved profitability this quarter, delivering approximately $2 million in positive adjusted EBITDA. MRD revenue grew 42% year-over-year, driven by significant increases in clinical volume.

Strong clonoSEQ Performance

clonoSEQ revenue grew 57% year-over-year in the second quarter, driven by strong demand across all reimbursed indications with over 25,300 tests delivered, up 37% versus prior year and 10% sequentially.

Improved Sequencing Gross Margin

Total company sequencing gross margin improved by 14 percentage points year-over-year to 64%.

Cash Position and Guidance Raise

Cash burn for the quarter was approximately $11 million, a 36% improvement over the same period last year, ending with a solid cash position of $222 million. Full year guidance was raised to reflect a higher MRD revenue range and a lower annual cash burn.

EMR Integration Expansion

clonoSEQ was integrated into Flatiron's OncoEMR across 113 community account groups and expanded Epic integration to 40 sites, resulting in accounts growing on average about 2x faster than nonintegrated accounts.

Positive Regulatory Developments

The European Medicines Agency, CHMP, issued a positive opinion supporting the use of MRD testing as an early endpoint for conditional approval in multiple myeloma.

Adaptive Biotechnologies (ADPT) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

ADPT Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 30, 2025	2025 (Q3)	-0.18 / -	-0.22	―	―	―
Aug 05, 2025	2025 (Q2)	-0.24 / -0.17	-0.31	45.16% (+0.14)
May 01, 2025	2025 (Q1)	-0.29 / -0.20	-0.33	39.39% (+0.13)
Feb 11, 2025	2024 (Q4)	-0.26 / -0.23	-0.48	52.08% (+0.25)
Nov 07, 2024	2024 (Q3)	-0.29 / -0.22	-0.35	37.14% (+0.13)
Aug 01, 2024	2024 (Q2)	-0.33 / -0.31	-0.33	6.06% (+0.02)
May 07, 2024	2024 (Q1)	-0.35 / -0.33	-0.4	17.50% (+0.07)
Feb 14, 2024	2023 (Q4)	-0.33 / -0.48	-0.28	-71.43% (-0.20)
Nov 09, 2023	2023 (Q3)	-0.34 / -0.35	-0.32	-9.37% (-0.03)
Aug 02, 2023	2023 (Q2)	-0.35 / -0.33	-0.37	10.81% (+0.04)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

ADPT Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 05, 2025	$11.05	$11.69	+5.79%
May 01, 2025	$7.36	$9.84	+33.70%
Feb 11, 2025	$7.80	$7.55	-3.21%
Nov 07, 2024	$5.63	$5.82	+3.37%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Adaptive Biotechnologies Corp (ADPT) report earnings?

Adaptive Biotechnologies Corp (ADPT) is schdueled to report earning on Oct 30, 2025, After Close (Confirmed).

What is Adaptive Biotechnologies Corp (ADPT) earnings time?

Adaptive Biotechnologies Corp (ADPT) earnings time is at Oct 30, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is ADPT EPS forecast?

ADPT EPS forecast for the fiscal quarter 2025 (Q3) is -0.18.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing